EBMT 2025

Chair: Professor Fabio Ciceri

Director of Hematology, Bone Marrow Transplantation Unit and Blood Bank San Raffaele Hospital, Milan

He is full professor of Hematology at Vita-Salute San Raffaele University since 2018 and Director the School of Specialization in Hematology. He is also Director of Comprehensive Cancer Center of San Raffaele Hospital.

His research has focused on advancing haploidentical transplantation as a therapeutic option for high-risk diseases. Since 1996, Professor Ciceri has led early clinical development in advanced cell therapy, gene therapy, and regenerative medicine, contributing to the first advanced cell therapy for blood cancer and HSC-based gene therapies for primary immunodeficiencies, metabolic diseases, and hemoglobinopathies. Professor Fabio Ciceri is member of several scientific organizations, past-President of  Italian Bone Marrow Transplantation Group (GITMO), current Scientific Chair of European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee ISCT-Europe & EBMT (JACIE). He is President of AISPO NGO leading implementation of Blood Banks and BMT Units in low-income countries.  

Dr Annalisa Ruggeri

Senior Physician, Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy

Annalisa Ruggeri received her Medical degree from University of Messina, Italy, in 2004. She completed her Hematology residency at the San Raffaele Vita-Salute University, Milano, Italy in 2008, and the PhD in Hematology in 2014.  She was staff member at the Hematology Department at the Saint Antoine Hospital in Paris, France and at Pediatric Hemato-oncology and cell and Gene therapy Department at the Ospedale Bambino Gesù in Roma, Italy. Since February 2020 she is senior physician at the Hematology and Bone Marrow Transplant unit of the San Raffaele Scientific Institute in Milano, Italy. She is active in clinical research activities being the scientific chair of the Eurocord office in Paris since 2012, and the current chair of the Cellular therapy and Immunobiology working party of the European society of Blood and Marrow transplantation (EBMT) since 2022. She is member of the ISCT- Stem cell source and graft engineering Committee. She is author of more than 200 peer-reviewed publications (H-index 53, Scopus) and has participated as invited speaker of many international conferences such American Society of Hematology (educational sessions), European society of Hematology and EBMT, ESH, ISCT, TCT. 

Dr Gloria Iacoboni

Hematologist, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Gloria Iacoboni is a Haematologist at the Vall d’Hebron Hospital, Barcelona, Spain. Prior to joining the hospital in 2017, Dr Iacoboni carried out a 1-year lymphoma fellowship at the Oncology Institute (IOSI) in Lugano, Switzerland. Dr Iacoboni specialises in new drug development for lymphoma treatment (including novel immunotherapeutic strategies) and has contributed to 69 publications in this field.

The publications include:  

• Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
• Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Aggressive B-Cell Lymphomas in the CART Era
• Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
• Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
• Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
• Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy 

Dr Miguel-Angel Perales

Chief of the Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, USA

Dr. Perales is the Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, Professor of Medicine at Weill Cornell Medical College and an internationally recognized leader in the field of hematopoietic stem cell transplantation and cellular therapy.

He is immediate past President of the American Society for Transplantation and Cellular Therapy (ASTCT) and serves as Chair of the Alliance for Clinical Trials in Oncology Transplantation and Cell Based Therapies Committee. He previously served as Vice-Chair and member of the Board of Directors of Be The Match (National Marrow Donor Program - NMDP). He has also held leadership positions and been extensively involved in activities of the Center for International Blood and Marrow Transplant Research (CIBMTR) and Blood and Marrow Transplantation Clinical Trials Network (BMT CTN). Dr. Perales has over 400 publications including peer-reviewed articles, position papers, guidelines, editorials, invited reviews and book chapters, and has been an invited speaker at numerous national and international meetings over the past twenty years.  Dr. Perales received his MD from the Free University of Brussels, and completed postdoctoral training at the Tufts Medical Center, Harvard Medical School and Memorial Sloan Kettering Cancer Center.

Dr Kate Cwynarski

Haem-Oncologist specialising in Lymphoma, University College London Hospital, London, UK

Dr. Kate Cwynarski is a Haem-Oncologist specialising in Lymphoma at University College London Hospital, London, UK, and Honorary Associate Professor at UCL. She trained at King's College, Hammersmith Hospital and Royal Free Hospital, London UK and received her MRC-funded PhD in Immunology at Imperial College, London, UK. Her sub-specialist interests include Central Nervous System (CNS) Lymphoma, T-cell Lymphomas, HIV-related, PTLD and high-grade Bcell lymphomas. She is involved in CAR-T cell trials for refractory DLBCL and T-cell lymphomas. 

She leads the UK T cell Lymphoma Group and previously lead the UK CNSL Group and British Society for Haematology (BSH) Lymphoma Specialist Interest Group. She is involved in clinical trials and has lead and co-authored BSH, EHA and BHIVA guidelines. She has co-authored over 100 journal articles in Nature Medicine, Lancet Haematology, Journal of Clinical Oncology, Blood and Leukaemia.